Jan Wald
Jan Wald
appears doctors faster fresh good perhaps portion willing
It appears that a good portion of doctors are willing to give Guidant a fresh look in their practices, and perhaps faster than most believed.
company hard indication processes
It is another indication that the processes could have been better ? but the company is working hard on it already.
actions company eventually expenses given remain stay
I think there are some actions the company will have to take and some expenses the company will have to incur that will make it tough. I still think given those parameters, it can be, stay and remain an independent company and eventually flourish.
growth jude needs people thinking walk
J&J needs something like Guidant to revitalize its growth. People are now thinking that if J&J does walk away, St. Jude is in their scopes.
needs
J&J needs something like Guidant to revitalize its growth,
hard people work
People are Guidant's most important asset, ... so there are hard trade-offs for Guidant to work through.
boston buying good insider investors scientific
I think investors do take insider buying as a good sign, and I think they especially wanted Boston Scientific to do it.
time
But that is an awfully long time to look out for pharmaceuticals.
feeling
I have a feeling that Temecula is pretty safe.
along believe boston deal matter small strategic
I don't believe these things are going to matter for Boston Scientific. This is a strategic deal for them and these are small perturbations along the way.
boston deal power reach scientific
Boston Scientific will do everything in its power to reach a deal with Guidant.
boston company fda gain permit product quality saying scientific seemed until
What the FDA seemed to be saying is that it doesn't know if Boston Scientific has a systemic, corporate-wide quality policy, and until it does the FDA will not permit the company to gain product approvals in adulterated plants.
acquire growth investors rate
My sense is J&J is going to have to acquire to get a growth rate that investors will think is respectable.
company education loses market money training
One thing the company loses by not being part of J&J is not having more money for market development education and training